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Prognostic stratification is critical for making therapeutic decisions and 
maximizing survival of patients with acute myeloid leukemia. Advances in the 
genomics of acute myeloid leukemia have identified several recurrent gene 
mutations whose prognostic impact is being deciphered. We used HaloPlex 
target enrichment and Illumina-based next generation sequencing to study 24 
recurrently mutated genes in 42 samples of acute myeloid leukemia with a 
normal karyotype. Read depth varied between and within genes for the same 
sample, but was predictable and highly consistent across samples. Consequently, 
we were able to detect copy number changes, such as an interstitial deletion of 
BCOR, three MLL partial tandem duplications, and a novel KRAS amplification. 
With regards to coding mutations, we identified likely oncogenic variants in 
41/42 samples. NPM1 mutations were the most frequent, followed by FLT3, 
DNMT3A and TET2. NPM1 and FLT3 indels were reported with good efficiency. 
We also showed that DNMT3A mutations can persist post-chemotherapy and in 2 
cases studied at diagnosis and relapse, we were able to delineate the dynamics of 
tumor evolution and give insights into order of acquisition of variants. HaloPlex 
is a quick and reliable target enrichment method that can aid diagnosis and 






Acute myeloid leukemia (AML) is a heterogeneous group of hematological 
malignancies characterized by a differentiation block and unrestricted 
proliferation of myeloid precursors. Historically, AML classification was based on 
phenotypic criteria of the French-America-British (FAB) co-operative group1. 
More recently, the World Health Organization (WHO), formulated an updated 
classification based on key genetic lesions underlying distinct clinico-
pathological subgroups2. With the exception of FAB AML-M3 (acute 
promyelocytic leukemia), there is limited overlap between subgroups of the FAB 
and WHO classifications. As recent clinical advances in AML have been driven by 
better prognostic stratification3, the WHO classification has rapidly made its way 
into routine clinical practice in view of its prognostic and therapeutic 
implications.  
 
However, advances in AML genomics4,5 have demonstrated that even within 
WHO classes there exists significant heterogeneity, which can translate into 
different clinical outcomes6. This is particularly true of patients with normal 
karyotype AML (AML-NK), who could be either over- or under-treated in the 
absence of prognostic information. In fact, AML-NK is driven by a complex 
interplay of several diverse leukaemogenic mutations that may confer different 
prognosis based on their combinatorial patterns of co-occurrence. For example, 
the good prognostic value of NPM1- or CEBPA-mutations6-8 is annulled by the 
presence of FLT3 internal tandem duplications (FLT3-ITDs)9,10, in the same way 
as c-KIT mutations can negate the good prognostic impact of core binding factor 
translocations11. Similarly, other genes or gene combinations appear to carry 
prognostic value5,12, and this is being assessed in large patient cohorts. 
Additionally, gene mutations may serve as therapeutic targets as shown for 
example by the clinical efficacy of the tyrosine kinase inhibitor dasatinib for AML 
with c-KIT mutations 13,14, and by therapies targeting FLT3-ITD15. 
 
Next generation sequencing (NGS) technologies introduced rapid sequencing of 
entire human genomes16. AML with normal karyotype was the first cancer whose 
 5
genome was fully sequenced17, and the spectrum of its genomic alterations has 
since been characterized in hundreds of patients4. Several technologies are now 
available that selectively enrich for relevant genes/regions (target enrichment) 
before NGS is performed. This allows for cheaper multiplexed sequencing of 
more cases, and moderates the complexity of downstream bioinformatics 
analyses. Such an approach, employing DNA pulldown with cRNA probes 
(Sureselect®, Agilent Technologies) was recently described in AML18 and 
myelodysplastic syndromes19,20. However, this approach suffers from the need 
for laborious library preparation, long turnaround times and reduced sensitivity 
for detecting long insertions such as FLT3-ITDs18. In this study, we employed the 
HaloPlex® (Agilent Technologies) target enrichment system, which is based on 
digestion of genomic DNA to produce fragments tiling target regions, followed by 
sequence-specific annealing to custom-made probes followed by PCR-
amplification to produce tagged amplicons for sequencing. This system uses little 
input DNA and promises a more affordable, quick, and efficient target 
enrichment that may be more suitable for analysis in diagnostic laboratories21. 
We used HaloPlex to study 24 recurrently mutated genes in 42 AML samples, 
mostly in the absence of matched normal DNA. Here we report its performance 
in identifying coding and copy number mutations affecting target genes. 
 
Methods 
Samples, DNA target enrichment, sequencing and alignment 
DNA was extracted from bone marrow of 40 AML-NK patients with >80% 
leukemic infiltrate at diagnosis. All patients had either karyotyping or multiplex 
PCR to rule out recurrent chromosomal translocations (HemaVision®-Screen, 
DNA Diagnostic A/S). Tumor samples were compared to an unrelated normal 
DNA sample (human placenta) for variant calling. For 2 patients we collected 
bone marrow samples at diagnosis and at molecular relapse, identified by 
increased NPM1/ABL ratio by RT-qPCR. For 5 patients a matched bone marrow 
sample was also available post-chemotherapy. Informed consent was obtained 
within our ethics-approved study (IRB 07/MRE05/44) and samples were stored 
in accordance with the declaration of Helsinki. The 24 genes studied were 
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selected based on their recurrence rate in AML and their relevance to 
pathogenesis and prognosis (Table 1). The targeting design was generated using 
an on-line design tool for HaloPlex and target enrichment was performed using 
HaloPlex standard protocol (version 2.0, November 2011). Briefly, 900 ng of 
DNA per sample were aliquoted into 8 digestion reactions, each containing 2 
restriction enzymes. DNA from the 8 reactions was then pooled, hybridized to 
HaloPlex probes, and purified using magnetic beads. Fragments were ligated, 
amplified and barcoded through 19 PCR cycles and two pools of 12 and 35 
samples sequenced on one lane each of HiSeq2000 (Illumina), 100 bp paired-end 
protocol.  
Before alignment, 5 bp were trimmed from the start of each read to minimize 
possible mis-mapping due to restriction site sequence retention. Paired-end 
sequencing reads were aligned to the human genome (NCBI build 37) using 
BWA22. Unmapped or off-target reads were excluded. Apparent PCR duplicates 
were not removed as HaloPlex generates fragments of the same start and end 
positions that cannot be distinguished from each other before or after PCR. 
 
On-target performance and copy-number analysis 
To determine the coverage of the target region, we used a BED file encoding the 
coordinates of the coding sequence of each of the 24 genes and retrieved the 
number of reads covering each base-pair position using Bedtools v2.1523. We 
then normalized coverage in each sample by dividing the read count at each 
position by the total number of on-target mapped bases for that sample. 
Coverage data and plots were produced using open-source software and bespoke 
R scripts (R v3.0.3)24. To identify copy number variants at individual exons, we 
compared the average coverage of each exon with that of normal samples. Genes 
with three or more exons showing read depths above or below the standard 





Mutation calling algorithms 
Substitutions and insertions/deletions were detected using CaVEMan and Pindel 
as previously described19,25,26. Our main aim was to define driver events and 
therefore we only reported “likely oncogenic variants”, defined as variants 
already reported as somatic in AML literature, or novel variants clustering with 
known somatic variant hotspots, or truncating variants in genes implicated in 
AML through loss of function mutations. Relevant variants and copy number 
events were validated with orthogonal techniques. More details are provided in 
the supplementary material. 
Results 
Patients and sequencing metrics 
The target region of 140,811bp did not include UTRs or introns and was 
sequenced with a mean coverage of 3,655x (total output 39.91 gigabases (Gb)) 
(Figure 1A). The number of bases mapped on-target per sample was dependent 
on the degree of multiplexing and ranged from 0.13 to 1.26Gb (Figure 1A), 
representing an average of 66.33% of the total output. Unsurprisingly, there was 
a correlation between the depth of sequencing and the percentage of the target 
region covered at >1000x (p <2.2e-16, Figure 1A) and at >30x, which we 
consider the minimum depth for reliable analysis (p=0.04, Figure 1A). Coverage 
of each gene varied between samples depending on total sequencing output 
(Figure 1B), as did coverage of different genes within the same sample 
presumably due to factors such as PCR efficiency and GC content. Nevertheless, 
our study performed well as all genes were covered at >30x for at least 90% of 
their coding regions with the exception of the GC rich and notoriously hard to 
target CEBPA19 (Figure 1C).  
 
Factors affecting local coverage  
Each fragment/read of HaloPlex target enrichment has a defined start site unlike 
target enrichment generated using shearing, which produces fragments with 
different start and end points. We therefore asked whether the position of 
restriction sites could influence coverage of target regions. 
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We found significant variability looking at raw coverage across gene loci within 
each sample, with read depth following a “square wave” pattern. For example, 
coverage across consecutive bases of the CEBPA locus varied by several fold 
(Figure 2A), with drops in coverage likely dictated by PCR amplification 
differences as well as number and size of amplicons. Some reads of our 100 bp 
paired-end sequencing did not reach the middle portion of the few large 
amplicons longer than 200bp (Figure 2B) due to positions of restriction sites 
used in the genome. Therefore, we investigated whether amplicon length 
correlated with coverage across the entire target region. Coverage of amplicons 
<100bp was variable, whilst amplicons longer than 200 bp showed a percentage 
of missed bases that increased proportionally with their length (Figure 2C). 
Unsurprisingly, we found that coverage at each base-pair position strongly 
correlated with the number of amplicons covering it (Figure 2D), suggesting that 
tiling more amplicons over a region rescued coverage gaps in long amplicons. 
This also explains why not all amplicons longer than 200 bp demonstrate a drop 
in coverage (Figure 2C), as this phenomenon was mainly limited to regions 
covered by single amplicons. Finally, we asked if coverage was influenced by 
length of exons rather than amplicons, and we found that this was not the case 
(Figure 2E), again suggesting that tiling regions of interest with multiple 
amplicons can overcome gaps of coverage within long amplicons. Our data show 
therefore that the regional drops in coverage of HaloPlex target enrichment are 
predictable based on amplicon length and tiling, and not influenced by the size of 
the region/feature of interest. These factors should be considered as part of 
HaloPlex target enrichment designs. 
 
Detection of copy-number changes 
We observed that coverage varied significantly between different base positions 
from the same sample, however coverage patterns appeared consistent between 
samples. In this context, we asked whether HaloPlex target enrichment data 
could identify copy number aberrations, as is the case for SureSelect target 
enrichment18,19. We normalized coverage of each sample for on-target mapped 
bases, and plotted average depth for all genes in our samples (Figure 3A). All 
 9
samples showed read depths for X- and Y- chromosome genes consistent with 
patient gender, with females consistently showing a ~2 fold increase in coverage 
of X-linked genes (BCOR and KDM6A, also known as UTX) and no coverage of the 
Y-linked gene UTY (the Y homolog of KDM6A). Interestingly one male sample, 
PD19747a, showed a BCOR depth that was lower than other males in the cohort 
(black bar in Figure 3A). Coverage of all BCOR exons was significantly lower 
compared to the average of normal male samples (Figure 3B), suggesting this 
patient carries a BCOR deletion and this was indeed confirmed by quantitative 
PCR (Figure 3C). As sample PD17940a was previously shown to carry a MLL 
partial tandem duplication (PTD)18, we checked coverage of MLL exons between 
2 and 10 and found that most showed a higher coverage than normal samples 
(Figure 3D) consistent with a duplication of the region. We found another 2 
patients showing the same pattern (PD17948a and PD17957a, Figure 3D), and 
went on to confirm the presence of MLL-PTDs by long-range PCR 
(Supplementary Figure S1A). Finally, one patient showed an amplification 
involving the KRAS locus (red bar in Figure 3A), which we confirmed by 
quantitative PCR (Figure 3E) and by CGH/SNP array (Supplementary Figure 1B).  
 
Given that read depth of gene loci returned a linear estimate of the copy number 
of the locus, we next looked at the quantitative value of substitution calls, and to 
this end we analyzed 90 of the most polymorphic SNPs within our target 
region27. 84.6% of the heterozygous SNP calls were confined in a narrow allelic 
fraction window of 50+/-10% (Supplementary Figure S1). 
Therefore, despite HaloPlex target enrichment returning variable coverage of 
different target regions, this variation is predictable, consistent across samples, 
and not significantly biased by PCR amplification. Depth of coverage retained 
quantitative value at the gene- and base-pair level and could identify copy 
number alterations with pathogenic and prognostic value. 
 
Study controls 
We next turned our attention to DNA sequence variants. First, we demonstrated 
that our algorithm identified likely oncogenic somatic variants and not inherited 
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polymorphisms without the use of matched normal DNA. We did this by 
comparing the 16 variants called by our unmatched variant detection pipeline to 
matched post-chemotherapy DNA in 5 patients for whom this was also available 
(Figure 4A). 13/16 mutations were not present in the post-chemotherapy 
sample suggesting these were somatic mutations. Of three patients showing 
persistence of one oncogenic variant each, two were in complete hematological 
remission and one in partial remission with normal blood counts. Interestingly, 
the two variants with high allelic frequency in the post-chemotherapy sample 
were DNMT3A R882H substitutions, recently reported to persist in pre-leukemic 
cells after AML remission28. The other, a TET2 nonsense mutation, showed a 
marked drop in allelic fraction consistent with incomplete molecular response. 
This shows that our pipeline can reliably identify somatic oncogenic events in 
unmatched samples, but underscores the limitation of using post-chemotherapy 
samples as matched controls in AML NGS studies. 
 
Next, we confirmed that HaloPlex identifies real variants by looking at the 25 
mutations found in 8 patients that were previously studied using SureSelect DNA 
pulldown18. These 25 variants included all 23 called by SureSelect18, including 
those present at subclonal level (Figure 4B), showing a high reliability of 
HaloPlex calls. An additional two variants were missed by SureSelect, both FLT3-
ITDs, which are notoriously hard to identify by targeted enrichment 
approaches18,29 (and Papaemmanuil E., Wellcome Trust Sanger Institute, 
personal communication, July 2014). Additionally, and notwithstanding the fact 
that the allelic burden of indels is hard to assess reliably, the correlation between 
allelic fractions of variants from the two enrichment methods was good, 
indicating that HaloPlex has similar quantitative properties to SureSelect.  
 
Caveman is a proprietary algorithm and thus we asked whether HaloPlex data 
would allow for reproducible results with other software. We compared 
Caveman substitution calls and allelic frequencies to those generated by SureCall 
(v1.1, Agilent Technologies). SureCall missed 23 of 61 substitutions detected by 
Caveman, including known oncogenic ones. All missed variants had an allelic 
burden <15%, suggesting that SureCall performs less well in detecting subclonal 
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variants (Figure 4C), although this may be surmountable by newer versions of 
the software. Nevertheless, for variants detected by both algorithms, the 
correlation between allelic frequencies was near perfect (Figure 4C).    
 
Because NPM1 and FLT3 indels are frequent variants and key prognostic 
indicators in AML-NK, we specifically evaluated the performance of the open 
source software Pindel in detecting these variants as compared to PCR-based 
genotyping. NGS and PCR were concordant on the FLT3-ITD status in 36/40 
evaluable samples (Figure 4D). In three cases, the ITD was found by PCR but not 
by NGS, and these were found to be large ITDs that may have not been amplified 
or mapped by BWA. In one case, a short ITD was only found by NGS, and we 
presume that it represented a subclonal event that PCR could not 
detect/discriminate. Conversely, Pindel only reported NPM1 C-terminal indels in 
7/26 cases shown to carry the mutation by PCR. Looking at NPM1 exon 12, we 
found a marked coverage drop of position chr 5:170837554, i.e. few bp away 
from the insertion site of most NPM1 indels. The reason for this was that all but 
one amplicons covering the region were >200bp long, and thus their midpoints 
were beyond the reach of either 100bp paired-end read (Figure 4E, bottom 
panel, arrowhead). This design pitfall also caused NPM1 indels to be close to the 
end of the reads, and thus discarded by Pindel and under-reported. Since only 
one amplicon covered the mutation in a position amenable to sequencing (Figure 
4E, asterisk), NPM1 variants were only called in samples where this amplicon 
was sequenced with enough coverage (p=0.01). Nevertheless, NPM1 indels from 
all amplicons were mapped by BWA, and visual inspection of the reads did allow 
their identification in all mutated cases (Figure 4F). To confirm that a short read 
length relative to the size of the amplicons covering the mutations was the 
reason for the poor detection of NPM1 indels, we re-sequenced HaloPlex libraries 
for 33 samples using MiSeq (Illumina) with a 150bp paired-end protocol. As 
expected, coverage of the NPM1 indel region was much higher (Figure 4E, green 
line), and all indels were called by Pindel (Figure 4G) with 100% sensitivity and 
specificity (Figure 4H). The presence of NPM1 mutations was further validated 
by capillary sequencing in all but one sample for which we did not have 
additional DNA (Supplementary Table S2).  
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Overall, 115 of 119 variants identified by HaloPlex were studied by PCR and/or 
MiSeq. Of the 103 that passed quality control, 96 were confirmed. Importantly, 
we could validate both clonal and subclonal variants indicating that HaloPlex can 
enrich target DNA allowing identification of variants across a range of allelic 
frequencies. Of the remaining 7 variants, 4 were false positives and 3 were 
sublclonal indels below the detection threshold of standard PCR  
(Supplementary Table S2). 
Gene mutations  
We reported 119 variants in 20 genes in 41 out of 42 samples, with a median of 3 
variants per sample (Figure 5A and Supplementary Table S2). The most 
frequently mutated gene was NPM1 (62%), followed by FLT3 (50%), DNMT3A 
and TET2 (33% and 29%, respectively). As previously described, there was a 
positive correlation between NPM1 mutations and FLT3 (p=0.008, Fisher’s 
exact). We also observed a tendency towards correlation between NPM1 and 
DNMT3A, and towards mutual exclusivity between TET2 and IDH1/2 mutations.   
Two or more FLT3-ITD alleles were identified in 3/14 samples. Allelic frequency 
couldn’t be reliably estimated in these indels making it impossible to determine 
if they occurred in the same cells (compound heterozygosity), or in different 
subclones of the tumor (convergent evolution). Similarly, two TET2 mutated 
alleles were found in 2/10 patients, reflecting a heterogeneous and evolving 
mutational pattern. Lastly, we annotated a p.S1018Y missense variant in UTY, a 
paralog of KDM6A not implicated in AML before. The variant was previously 
reported as somatic in a gastrointestinal cancer invoking a possible pathogenic 
role in AML. 
 
While allelic frequency can be used to assess the subclonal structure of tumors25, 
most of our variants were represented by indels and this precluded such 
analysis. Nevertheless, in two patients from whom paired diagnosis-relapse 
samples were available, we showed loss of a subclonal TET2 mutation in 
PD17932, and loss of a biallelic FLT3-ITD and a subclonal FLT3 N676K 
substitution in PD17936 at molecular relapse (Figure 5B). This confirms that the 
subclonal structure of AML can develop through continuous acquisition of 
 13
subclones with new driver mutations and loss of others, in a pattern consistent 
with branching evolution and differential sensitivity to chemotherapy as has 
been shown by others28,30.  
Discussion 
Dramatic advances in defining the somatic genome of AML4 have defined the 
major mutational drivers of this disease31. As a result, the field is ready for 
targeted follow-up studies aimed at better characterizing the prevalence, 
prognostic value and pathogenic role of these genetic lesions in large cohorts of 
patients. Indeed, information on mutated genes is making its way into new 
prognostic models5, especially in cases without recurrent karyotype 
rearrangements12. In this paper we describe a rapid, robust and high-throughput 
approach for the characterization of gene mutations and copy number changes in 
AML samples using HaloPlex target enrichment followed by NGS and standard 
bioinformatic analysis.  
 
We showed that amplicon tiling and read length relative to amplicon length are 
the two most important parameters affecting coverage of target regions. In 
HaloPlex, the position of restriction sites limits the extent to which sequencing 
start sites and amplicon lengths can be customized in the target enrichment 
design. Therefore, depending on tiling and amplicon length, adjacent genomic 
regions can show variable coverage. While the automated HaloPlex design tool 
works well in general, if mutational hotspots are anticipated it is advisable that 
these positions are checked manually to ensure they will be adequately covered. 
We showed that variability of coverage of HaloPlex data is reproducible and 
consistent across samples. Normalized coverage of each gene locus correlated 
with its copy number status, relative to the other samples in the cohort. This 
enabled us to identify small copy number changes without the need for matched 
normal DNA, as exemplified by the identification of three cases of MLL-PTDs. 
Furthermore, we report the novel finding that KRAS can be amplified and BCOR 
deleted in AML, reflecting the power of NGS techniques to interrogate tumor 
genomes in a high-throughput fashion. Clinical follow-up was not available for 
our patients, and future studies will define the recurrence rate and prognostic 
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role of these events in AML. Compared to genome-wide CGH arrays, we could 
only infer copy-number of regions targeted in our design. Nevertheless, in the 
future this property could be harnessed for the capture and study of a large 
number of polymorphic SNPs evenly spaced across the genome to allow the 
identification of whole-genome copy-number and loss-of-heterozygosity 
changes.  
 
Our study had a positive predictive value of 96% for the identification of 
recurrent mutations in AML. Its ability to report indels, a frequent event in AML, 
was especially good. Large genomic insertions such as MLL-PTDs were identified 
by copy-number profile of individual exons. While NPM1 indels were initially 
under-reported by 100bp reads because of a design flaw, employing longer reads 
allowed us to achieve 100% accuracy. We also found good efficiency for FLT3-
ITDs, as we identified 14/17 ITD samples. This was facilitated by targeting both 
FLT3 exons and introns around the breakpoints, although the allelic fraction of 
such events was lower than expected for driver mutations. Therefore, we could 
only capture and/or map a fraction of the mutated DNA molecules, and our 
detection sensitivity could have been lower had we not sequenced so deeply. 
Capture, mapping and quantification of FLT3-ITD alleles is a major challenge that 
will likely require bespoke targeting and bioinformatic approaches, especially for 
longer ITDs that were missed in our study29,32. On the other hand, we suggest 
that deep sequencing can provide increased sensitivity for short and subclonal 
ITDs that may be easily missed by conventional PCR, leading to incorrect 
prognostic characterization of the patient. Indeed, in our study we identified 3 
subclonal NPM1 and FLT3 indels that could not be confirmed by PCR followed by 
agarose gel electrophoresis or capillary sequencing. We believe these were true 
positive results, and the fact that other subclonal variants were validated in our 
study suggests their veracity. Subclonality in AML is increasingly recognized as a 
biological event with clinical implications28,30,33. HaloPlex target enrichment led 
to the identification and validation of a number of subclonal variants, and 
loss/gain of variants at AML relapse. This has the potential to inform on the 
order of acquisition of such variants during pre-clinical stages of leukemia 
development and suggests that future, larger studies may be able to inform 
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which variants are associated with better response to chemotherapy and which 
ones are most likely to confer chemoresistance. For example, our finding that 
TET2 mutations can be lost at relapse confirms that mutations in this gene can be 
late34 as well as early35 events in AML. Also, further studies will be required to 
assess the prognostic value of DNMT3A R882H persistence at morphological 
remission, and whether this variant should be used for assessment of minimal 
residual disease (MRD).  
We anticipate that NGS technologies will soon be used for a combined gene 
sequencing and copy number analysis of tumors, thus providing a one-stop 
diagnostic platform that has the potential to enhance current analysis relying on 
the integration of karyotype, FISH, PCR and RT-PCR data. Future studies with 
large numbers of patients and longitudinal follow-up will establish the diagnostic 
and prognostic value of recurrent abnormalities, and in our paper we show that 
HaloPlex target enrichment can provide a solid platform for this exercise. 
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Table 1. Genes and transcripts used for the targetd enrichment study 
gene NCBI RefSeq transcripts used (NCBI RefSeq ID) 
ASXL1 NM_001164603 NM_015338    
BCOR NM_017745 NM_001123385 NM_001123384 NM_001123383 
CBL NM_005188     
CEBPA NM_004364     
CSF1R NM_005211     
DNMT3A NM_022552 NM_153759 NM_175629 NM_175630 
FLT3 NM_004119     
EZH2 NM_152998 NM_004456    
IDH1 NM_005896     
IDH2 NM_002168     
JAK2 NM_004972     
KIT NM_001093772 NM_000222    
KDM6A NM_021140     
KRAS NM_004985 NM_033360    
MLL NM_005933     
NF1 NM_000267 NM_001042492 NM_001128147   
NPM1 NM_002520 NM_001037738 NM_199185   
NRAS NM_002524     
PTPN11 NM_002834     
RUNX1 NM_001001890 NM_001754 NM_001122607   
SF3B1 NM_012433 NM_001005526    
TET2 NM_001127208 NM_017628    
UTY NM_007125 NM_182659 NM_182660   




Legend to Figure 1 
A) Stacked bar chart showing the total sequence output in gigabases (Gb, left 
Y axis) per sample: grey, bases unmapped; yellow, bases mapped off 
target; blue, bases mapped on target. Samples plexed and sequenced in 
different HiSeq lanes are segregated by the dashed vertical line. Lines 
indicate the percentage of target covered at >30X (grey) and >1000X 
(red) – right Y axis. A Pearson’s test shows the correlation between 
sequence output and percentage of target covered at the above 
percentages.  
B) Bar chart displaying the absolute coverage of each gene in the study, 
calculated as the mean coverage of that gene in all samples. Error bars 
represent standard deviation. 
C) Bar chart showing, for each gene, the average percentage of the coding 
region covered at >30X in all samples (i.e., the minimum coverage used 
for variant calling). Error bars represent standard deviation. UTY, the Y 
chromosome homologue of KDM6A (UTX), was only covered by males in 
the study. 
 
Legend to Figure 2 
A) Line graph showing base-by-base average normalized coverage of the 
CEBPA gene footprint. The CEBPA coding region is shown by a thick blue 
bar, and the UTR regions by a thin blue bar. The horizontal red line 
highlights positions not covered (0 bp coverage). Below, the amplicons 
from HaloPlex design are shown in green. 
B) Boxplot showing the distribution of amplicon size in the design. The 
central line is the median, and the box includes values between the first 
and third quartile. 
C) Plot showing, for each amplicon in the design (blue dots), the relation 
between its length (X axis) and the percentage of its bases covered at 
>30X. Note that the coverage drops in a fraction of amplicons longer than 
200 bp (i.e. the combined length of the paired-end sequencing protocol), 
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suggesting that the middle region of such large amplicons wasn’t covered 
by either of the 100bp paired-end reads, and no other amplicons were 
overlapping on that region. 
D) Boxplot showing, for each base in the design, the positive correlation 
between the number of amplicons covering it (X axis) and its average 
coverage in all samples (Y axis). The central line is the median, and the 
box includes values between the first and third quartile. 
E) Plot showing that coverage (Y axis) of individual exons (blue dots) in the 
design is independent of their length (X axis, in log scale). 
 
Legend to Figure 3 
A) For each gene in the study, the normalized average depth of coverage (Y 
axis) is plotted individually for all patients (X axis) on a linear arbitrary 
scale.  
B) PD17947a (black bar) shows a BCOR deletion involving all exons, whose 
coverage is lower than the average coverage of three normal male 
samples (white bar). The residual signal from all BCOR exons in 
PD17947a likely reflects that the deletion is subclonal, although a 
percentage of normal cells admixed in the tumor sample must also be 
taken into account. In the particular case of BCOR exon 5 the ratio 
between WT samples and PD17947a is different compared to 
neighboring exons, but this must be interpreted with caution. This exon 
showed the lowest coverage of all BCOR exons and a high number of 
homologous regions that could lead to mismapping and make it 
insensitive to copy number changes.  
C) Quantitative PCR on genomic DNA shows lower levels of BCOR exons 1 
and 4 in PD17947a (black, solid and dashed bar respectively) compared 
to a control male sample (PD17948a, yellow). 
D) PD17940a, PD17948a, and PD17957a (green, yellow and blue bars, 
respectively) show a MLL partial tandem duplication as shown by 
increased coverage of most exons between 1 and 10 compared to the 
average of 5 normal samples (white bars).  
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E) PD17946a (red bar) shows a KRAS amplification confirmed by qPCR on 
genomic DNA compared to a control sample in the study. 
Legend to Figure 4 
A) For 5 patients in the study where a post-chemotherapy sample was 
available, the somatic status of 16 variants was checked. Y axis represents 
the raw allelic fraction of the variant, and X axis represents individual 
variants, clustered by patient, in the tumor (blue bar) and remission 
sample (yellow). Note that DNMT3A R882H persists at a similar allelic 
fraction in post-chemotherapy samples, independent of the remission 
status of the patient. Also, the persistence of a low-level TET2 p.L1119* 
nonsense mutation suggests that patient had a partial molecular response 
to treatment. 
B) For 25 variants, validation data was available from a previous study 
performed with SureSelect target enrichment. The plot shows the allelic 
fraction of variants in the HaloPlex study (X axis) and that of the 
Sureselect study (Y axis). Variants are represented as solid circles 
(substitutions) or open triangles (indels), and are blue if shared between 
the two studies and yellow if only reported by the HaloPlex study. The 
plot shows good correlation of allelic fraction between the two studies. 
C) For the 61 substitutions in the study, two different algorithms were 
compared (CaVEMan and SureCall). Shared variants are in blue, variants 
missed by SureCall are in yellow. For the shared variants, the correlation 
between allelic fractions is near perfect. 
D) For 40 samples in the study (X axis), FLT3-ITDs are plotted by length (Y 
axis, value=0 if no ITD present). Variants confirmed by both Pindel and 
PCR are blue circles, those only found by PCR are yellow upwards 
triangles, and those only found by NGS are yellow downwards triangles. 
E) Top: the black line shows base-by-base average normalized coverage of 
the NPM1 gene locus. The NPM1 coding region is shown by a thick blue 
bar, and the UTR regions by a thin blue bar. Below, predicted amplicons 
from HaloPlex design are shown in green.  
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Bottom: zoomed-in view of NPM1 exon 12. Coverage by 100 bp reads is 
shown as a black line and leaves a 1-bp gap close to the NPM1c+ insertion 
site. The amplicon closer to NPM1c+ mutations and allowing their 
identification is highlighted by an asterisk, while the amplicons where 
such mutations were missed are marked by an arrowhead. When 150 bp 
reads are employed (green line), coverage of the middle region increases.  
F) Aligned reads from a 100 bp sample where the mutation was missed 
because of short read length leaving a gap in coverage (arrow). Yellow: 
reverse reads. Blue: forward reads. The presence of the indel must be 
deducted by the BWA calls (red boxes, arrowheads). 
G) Aligned reads from a 150 bp sample where the mutation was identified. 
Yellow: reverse reads. Blue: forward reads. The insertion is identified by 
Pindel as green boxes (arrow). 
H) Stacked bar chart showing the increase in sensitivity of Pindel for 
detection of NPM1 indels with a 150bp protocol. 
 
Legend to Figure 5 
A) Table highlighting relevant genetic alterations and recurrently mutated 
genes in the study. Samples are represented in columns. Recurrently 
mutated genes are color-coded for missense (blue), nonsense (red), 
splice-site (green) substitutions, and indels (yellow). In case of multiple 
mutations of the same class in a gene in a patient, a black contour is 
drawn. If two mutations of different class are present, the box is filled by 
two triangles. For each gene, the number of patients harboring at least 
one non-silent mutation is provided in the ‘TOTAL’ column.  
B) For two patients where diagnosis (D) and relapse (R) samples where 
available, the mutational spectrum is provided to show evolution of the 
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Sequence	  variant	  detection	  and	  filtering	  criteria	  
Base	   substitutions	   and	   small	   insertions	   or	   deletions	   were	   identified	   by	  
comparison	   of	   42	   MDS	   samples	   against	   unmatched	   normal	   samples	   using	  
established	  bioinformatics	  algorithms1-­‐3.	  To	  account	  for	  the	  absence	  of	  matched	  
control	   a	   bespoke	   variant	   selection	   pipeline	   was	   developed.	   Each	   putative	  
variant	  was	  annotated	  using	  the	  following	  resources:	  
1. Known	   constitutional	   polymorphisms	   using	   known	   human	   variation	  
databases,	  Ensembl	  GRCh37.5,	  1000	  genomes	  release	  2.2.2	  and	  ESP65004	  5.	  
2. Known	   somatic	   variation	   in	   myeloid	   and	   other	   common	   malignancies	   as	  
reported	  in	  COSMIC	  v676.	  
3. Exome	   or	  whole	   genome	   sequencing	   data	   derived	   from	  317	   constitutional	  
DNA	  samples	  analyzed	  in	  CGP	  (CGP	  normal	  panel).	  	  
4. Sequence	   context	   5’	   and	   3’	   to	   the	   reported	   sequence	   change	   highlighting	  
regions	   of	   homopolymer	   sequences	   that	   are	   prone	   to	   PCR	   slippage	   and	  
artifacts	   altering	   the	   last	   base	   of	   the	   homopolymer	   or	   inserting	   the	   same	  
base	  as	  the	  homopolymer	  at	  +1,	  +2	  of	  the	  track.	  
5. Variant	   specific	  metrics	   to	   include	  protein	  annotation,	   sequence	  depth	  and	  
%	  of	  reads	  reporting	  the	  variant	  allele.	  
	  
	  
To	  enrich	   for	  high-­‐confidence	  somatic	  variants	   that	   impact	  on	  protein	   function	  
further	  filtering	  was	  conducted	  using	  the	  following	  criteria:	  
1. Removal	  of	  all	  variants	  with	  a	  predicted	  effect	  of	  a	  silent	  amino	  acid	  change	  
on	  all	  transcripts	  corresponding	  to	  each	  gene.	  
2. Removal	  of	  known	  polymorphisms	  present	  in	  either	  of	  the	  human	  variation	  
databases	   at	   a	   population	   frequency	   >	   0.0014	   (reflecting	   the	   population	  
incidence	   of	   myeloid	   disease	   and	   potentially	   rare	   variants	   that	   could	   be	  
associated	   with	   myeloid	   malignancies)	   unless	   variant	   is	   present	   as	  
confirmed	  somatic	  mutation	  in	  COSMIC.	  
3. Removal	  of	  known	  polymorphisms	  present	  in	  human	  variation	  databases	  at	  
a	   population	   frequency	   <	   0.0014	   and	   also	   represented	   in	   the	   extended	  
normal	   CGP	   panel,	   available	   form	   in	   house	   exome	   and	   whole	   genome	  
sequencing	  projects.	  
4. Retention	   of	   all	   variants	   present	   in	   human	   variation	   databases	   at	   a	  
population	   frequency	   <	   0.0014	   and	   also	   present	   in	   COSMIC	   as	   confirmed	  
somatic	  in	  Haematopoietic	  tissue.	  
5. Removal	  of	  all	  sequence	  variants	  that	  were	  represented	  in	  at	  least	  2	  normal	  
individuals	   in	   the	   CGP	   normal	   panel	   with	   a	   minimum	   variant	   allele	  
proportion	  of	  10%.	  
6. Removal	   of	   variants	   present	   within	   regions	   prone	   to	   sequence	   context	  
specific	  artifacts,	   including	  regions	  of	  high	  depth,	  enriched	  for	  reads	  of	   low	  
mapping	  quality	  that	  harbor	  multiple	  mismatches.	  
7. Removal	   of	   all	   1bp	   insertions	   or	   deletions	   present	   adjacent	   to	   regions	   of	  
more	  than	  5	  homopolymer	  bases	  (i.e	  insA	  adjacent	  to	  AAAAA)	  and	  a	  variant	  
allele	  proportion	  of	  <	  12%	  and	  evidence	  of	  occurrence	  in	  CGP	  normal	  panel;	  
	  
Once	   low	  confidence	  or	   likely	  polymorphisms	  were	   removed	   from	   the	  dataset,	  
likely	  oncogenic	  were	  annotated	  and	  selected	  for	  the	  study	  among	  the	  shortlist	  
of	  high	  confidence	  variants	  in	  accordance	  to	  prior	  evidence	  in	  the	  literature.	  To	  
reflect	  the	  confidence	  that	  one	  would	  use	  these	  as	  diagnostic	  biomarkers	  in	  the	  
clinic,	  variants	  were	  annotated	  conservatively,	  so	  that	  we	  only	  reported	  known	  
oncogenic	   variants	  previously	   reported	   in	   the	   literature,	   or	  novel	   variants	   that	  
cluster	   with	   known	   somatic	   variants	   in	   cancer	   driver	   genes,	   or	   truncating	  
variants	  (nonsense	  mutations,	  essential	  splice	  mutations	  or	  frameshift	  indels)	  in	  




Copy	   number	   alterations	   of	   KRAS	   and	   BCOR	  were	   validated	   on	   genomic	   DNA	  
with	  SYBRgreen	  quantitative	  PCR	  using	   the	  ACTB	  gene	  as	   endogenous	   control,	  
and	   applying	   the	   ΔΔ CT	   method	   to	   perform	   a	   relative	   quantification7.	  
Furthermore,	   the	   copy	  number	  pattern	   identified	  by	  NGS	   in	   sample	  PD17946a	  
was	   validated	  using	   the	  Agilent	   SurePrint	  G3	   ISCA	  CGH+SNP	  Microarray.	  MLL-­‐
PTDs	   were	   validated	   by	   long	   range	   PCR	   as	   described	   in8.	   FLT3-­‐ITDs	   were	  
assessed	  on	  genomic	  DNA	  by	  PCR	  followed	  by	  either	  agarose	  gel	  electrophoresis	  
or	  Bioanalyzer	  using	  a	  high	  sensitivity	  analysis	  kit	  (Agilent	  Technologies)	  for	  40	  
samples.	  NPM1	  exon	  12	  mutations	  were	  validated	  in	  33	  samples	  using	  genomic	  
DNA	  PCR	  followed	  by	  capillary	  sequencing.	  All	  primer	  sequences	  are	  provided	  in	  
Supplementary	  Table	  1.	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Supplementary	  Table	  S1.	  Primers	  used	  for	  PCR	  
validation	  
	   	  name	   Sequence	  (5'-­‐3')	  
BCOR_ex1_F	   TTTAGCACAGTCCTCCACCCCA	  
BCOR_ex1_R	   CATTCCGTTCAAACCCAGCAGC	  
BCOR_ex4_F	   CGGAAGACAGCGGTTCAAGACA	  
BCOR_ex4_R	   GTATCGCCCAGTCCAATGCCTT	  
ACTB_ex3_F	   GGAAGGAAGGCTGGAAGAGTGC	  
ACTB_ex3_R	   TGTGCTATCCCTGTACGCCTCT	  
KRAS_ex3_F	   CACTACCGATGCAGTCTGGAGC	  
KRAS_ex3_R	   GGACTGGGGAGGGCTTTCTTTG	  
NPM1_F	   ATTGGCCATATGGGTCTCTG	  
NPM1_R	   AACACGGTAGGGAAAGTTCTCA	  
FLT3-­‐ITD_F	   GCAATTTAGGTATGAAAGCCAGC	  
FLT3-­‐ITD_R	   CTTTCAGCATTTTGACGGAACC	  
MLL-­‐6.1	   GTCCAGAGCAGAGCAAACAG	  	  
MLL-­‐2.0	   CGCACTCTGACTTCTTCATC	  	  
	  
Supplementary	  Table	  S2.	  Variants	  identified	  in	  the	  study	  and	  their	  validation	  
	   	   	   	   	   	   	   	   	   	   	  Algorith
m	   Sample	   CHR	   START	   END	   Gene	   Transcript	   Protein	   Effect	   Validation	  method	   Validation	  outcome	  
Pindel	   PD17929a	   13	   28608280	   28608281	   FLT3	   CCDS31953.1	   p.D600_L601insDFREYEYD	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Pindel	   PD17929a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17929a	   13	   28608290	   28608298	   FLT3	   CCDS31953.1	   p.E598_Y599insNEYFYVDFREYE	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17929a	   20	   31022938	   31022938	   ASXL1	   CCDS13201.1	   p.P808H	   missense	   MiSeq	   validated	  
Caveman	   PD17929a	   2	   209113112	   209113112	   IDH1	   CCDS2381.1	   p.R132L	   missense	   MiSeq	   validated	  
Pindel	   PD17930a	   2	   25463299	   25463300	   DNMT3A	   CCDS33157.1	   p.E733fs*1	   frameshift	   MiSeq	   validated	  
Pindel	   PD17930a	   13	   28608271	   28608272	   FLT3	   CCDS31953.1	   p.K602_W603insEYEYDLK	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Pindel	   PD17930a	   13	   28608274	   28608275	   FLT3	   CCDS31953.1	   p.E608_N609insYEYDLKWEFPRE	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17930a	   2	   209113113	   209113113	   IDH1	   CCDS2381.1	   p.R132S	   missense	   MiSeq	   validated	  
Pindel	   PD17930a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17931a	   13	   28608286	   28608287	   FLT3	   CCDS31953.1	   p.Y597_E598insDYVDFREY	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17931a	   2	   25457242	   25457242	   DNMT3A	   CCDS33157.1	   p.R882H	   missense	   MiSeq	   validated	  
Caveman	   PD17931a	   4	   106180928	   106180928	   TET2	   CCDS47120.1	   p.?	   ess	  splice	   MiSeq	   validated	  
	  
PD17931a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17932a	   13	   28608280	   28608281	   FLT3	   CCDS31953.1	   p.D600_L601insFREYEYD	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17932a	   2	   25467449	   25467449	   DNMT3A	   CCDS33157.1	   p.G543C	   missense	   MiSeq	   validated	  
Caveman	   PD17932a	   4	   106156570	   106156570	   TET2	   CCDS47120.1	   p.Q491K	   missense	   MiSeq	   No	  coverage	  
	  
PD17932a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17932c	   13	   28608280	   28608281	   FLT3	   CCDS31953.1	   p.D600_L601insFREYEYD	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17932c	   2	   25467449	   25467449	   DNMT3A	   CCDS33157.1	   p.G543C	   missense	   MiSeq	   validated	  
	  
PD17932c	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   not	  confirmed	  
Caveman	   PD17933a	   2	   25463182	   25463182	   DNMT3A	   CCDS33157.1	   p.R771*	   nonsense	   MiSeq	   validated	  
Caveman	   PD17933a	   19	   33792981	   33792981	   CEBPA	   ENST00000498907	   p.G114C	   missense	   MiSeq	   validated	  
	  
PD17933a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17934b	   2	   25457243	   25457243	   DNMT3A	   CCDS33157.1	   p.R882C	   missense	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17934b	   13	   28592642	   28592642	   FLT3	   CCDS31953.1	   p.D835Y	   missense	   SureSelect	  +	  NGS	   validated	  
	  
PD17934b	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17935a	   4	   106158455	   106158455	   TET2	   CCDS47120.1	   p.L1119*	   nonsense	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17935a	   12	   25378647	   25378647	   KRAS	   CCDS8703.1	   p.K117N	   missense	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17936a	   15	   90631934	   90631934	   IDH2	   CCDS10359.1	   p.R140Q	   missense	   SureSelect	  +	  NGS	   validated	  
Pindel	   PD17936a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   PCR	  failure	  
Pindel	   PD17936c	   13	   28608280	   28608281	   FLT3	   CCDS31953.1	   p.D600_L601insFREYEYD	   frameshift	   PCR	  +	  agarose	  gel	   not	  confirmed	  
Caveman	   PD17936c	   15	   90631934	   90631934	   IDH2	   CCDS10359.1	   p.R140Q	   missense	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17936c	   13	   28602340	   28602340	   FLT3	   CCDS31953.1	   p.N676K	   missense	   SureSelect	  +	  NGS	   validated	  
Pindel	   PD17936c	   13	   28608288	   28608302	   FLT3	   CCDS31953.1	   p.E608_N609insDNEYFYVDFREYEYDLKWEFPRE	   frameshift	   PCR	  +	  agarose	  gel	   not	  confirmed	  
Pindel	   PD17936c	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17937c	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17937c	   2	   209113112	   209113112	   IDH1	   CCDS2381.1	   p.R132H	   missense	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17937c	   13	   28592642	   28592642	   FLT3	   CCDS31953.1	   p.D835Y	   missense	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17937c	   1	   115258748	   115258748	   NRAS	   CCDS877.1	   p.G12S	   missense	   SureSelect	  +	  NGS	   validated	  
Pindel	   PD17938a	   13	   28608308	   28608309	   FLT3	   CCDS31953.1	   p.E598_Y599insCRSSDNEYFYVDFREYE	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17938a	   2	   25457242	   25457242	   DNMT3A	   CCDS33157.1	   p.R882H	   missense	   MiSeq	   validated	  
Caveman	   PD17938a	   12	   112940014	   112940014	   PTPN11	   CCDS9163.1	   p.D556Y	   missense	   MiSeq	   No	  coverage	  
	  
PD17938a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17939a	   19	   33792393	   33792394	   CEBPA	   ENST00000498907	   p.E309_T310insN	   inframe	   SureSelect	  +	  NGS	   validated	  
Pindel	   PD17939a	   11	   32456252	   32456254	   WT1	   CCDS7878.2	   p.N214fs*36	   frameshift	   SureSelect	  +	  NGS	   validated	  
Pindel	   PD17939a	   13	   28608288	   28608291	   FLT3	   CCDS31953.1	   p.Y597_E598insDFYVDFREY	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17939a	   1	   115258747	   115258747	   NRAS	   CCDS877.1	   p.G12D	   missense	   SureSelect	  +	  NGS	   validated	  
	  
PD17939a	   19	   33792982	   33792983	   CEBPA	   ENST00000498907_r69	   p.A111fs*56	   frameshift	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17940a	   20	   31022297	   31022297	   ASXL1	   CCDS13201.1	   p.C594*	   nonsense	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17940a	   12	   25398284	   25398284	   KRAS	   CCDS8703.1	   p.G12V	   missense	   SureSelect	  +	  NGS	   validated	  
Pindel	   PD17941a	   2	   25467105	   25467109	   DNMT3A	   CCDS33157.1	   p.G590fs*61	   frameshift	   SureSelect	  +	  NGS	   validated	  
Caveman	   PD17941a	   15	   90631838	   90631838	   IDH2	   CCDS10359.1	   p.R172K	   missense	   SureSelect	  +	  NGS	   validated	  
Pindel	   PD17942a	   13	   28608286	   28608287	   FLT3	   CCDS31953.1	   p.Y597_E598insDYVDFREY	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17942a	   2	   25457242	   25457242	   DNMT3A	   CCDS33157.1	   p.R882H	   missense	   MiSeq	   validated	  
Caveman	   PD17942a	   2	   209113113	   209113113	   IDH1	   CCDS2381.1	   p.R132C	   missense	   MiSeq	   validated	  
	  
PD17942a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17943a	   15	   90631934	   90631934	   IDH2	   CCDS10359.1	   p.R140Q	   missense	  
	   	  
	  
PD17943a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17944a	   20	   31022412	   31022413	   ASXL1	   CCDS13201.1	   p.H633fs*2	   frameshift	   MiSeq	   validated	  
Caveman	   PD17945a	   1	   115256536	   115256536	   NRAS	   CCDS877.1	   p.A59S	   missense	   MiSeq	   not	  confirmed	  
Caveman	   PD17945a	   7	   148508721	   148508721	   EZH2	   CCDS5891.1	   p.G648V	   missense	   MiSeq	   No	  coverage	  
	  
PD17945a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17946a	   4	   106156658	   106156660	   TET2	   CCDS47120.1	   p.S521fs*1	   frameshift	  
	   	  
Caveman	   PD17946a	   21	   36231774	   36231774	   RUNX1	   CCDS13639.1	   p.R204*	   nonsense	   MiSeq	   validated	  
Caveman	   PD17946a	   20	   31022625	   31022625	   ASXL1	   CCDS13201.1	   p.G704R	   missense	   MiSeq	   No	  coverage	  
Caveman	   PD17946a	   4	   106164773	   106164773	   TET2	   CCDS47120.1	   p.R1214Q	   missense	   MiSeq	   not	  confirmed	  
Caveman	   PD17947a	   17	   29557890	   29557890	   NF1	   CCDS42292.1	   p.W1048C	   missense	   MiSeq	   not	  confirmed	  
Caveman	   PD17948a	   X	   44937750	   44937750	   KDM6A	   CCDS14265.1	   p.D980Y	   missense	   MiSeq	   validated	  
Caveman	   PD17949a	   2	   25458661	   25458661	   DNMT3A	   CCDS33157.1	   p.N838D	   missense	   MiSeq	   validated	  
Pindel	   PD17950a	   2	   25463567	   25463568	   DNMT3A	   CCDS33157.1	   p.I705fs*8	   frameshift	  
	   	  
Caveman	   PD17950a	   9	   5073770	   5073770	   JAK2	   CCDS6457.1	   p.V617F	   missense	  
	   	  
Pindel	   PD17951a	   11	   119149254	   119149274	   CBL	   CCDS8418.1	   p.I423_E427delIKGTE	   inframe	   MiSeq	   validated	  
Caveman	   PD17951a	   21	   36231774	   36231774	   RUNX1	   CCDS13639.1	   p.R204*	   nonsense	   MiSeq	   validated	  
Caveman	   PD17951a	   7	   148508719	   148508719	   EZH2	   CCDS5891.1	   p.E649*	   nonsense	   MiSeq	   No	  coverage	  
Pindel	   PD17952a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17953a	   4	   106157954	   106157955	   TET2	   CCDS47120.1	   p.R953fs*19	   frameshift	   MiSeq	   validated	  
Pindel	   PD17953a	   4	   106156406	   106156418	   TET2	   CCDS47120.1	   p.Y437fs*7	   frameshift	   MiSeq	   validated	  
Pindel	   PD17953a	   13	   28608316	   28608317	   FLT3	   CCDS31953.1	   p.E598_Y599insWVTGSSDNEYFYVDFREYE	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17953a	   X	   44938474	   44938474	   KDM6A	   CCDS14265.1	   p.A1008S	   missense	   MiSeq	   validated	  
	  
PD17953a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17954a	   15	   90631934	   90631934	   IDH2	   CCDS10359.1	   p.R140Q	   missense	   MiSeq	   validated	  
	  
PD17954a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17955a	   4	   106157812	   106157817	   TET2	   CCDS47120.1	   p.M906fs*17	   frameshift	   MiSeq	   validated	  
Caveman	   PD17955a	   4	   106164741	   106164741	   TET2	   CCDS47120.1	   p.S1203R	   missense	   MiSeq	   not	  confirmed	  
	  
PD17955a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17956a	   4	   106156348	   106156348	   TET2	   CCDS47120.1	   p.Q417*	   nonsense	   MiSeq	   validated	  
	  
PD17956a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17957a	   20	   31025013	   31025013	   ASXL1	   CCDS13201.1	   p.E1500*	   nonsense	   MiSeq	   validated	  
Caveman	   PD17957a	   2	   209113113	   209113113	   IDH1	   CCDS2381.1	   p.R132S	   missense	   MiSeq	   validated	  
Caveman	   PD17957a	   4	   106182965	   106182965	   TET2	   CCDS47120.1	   p.P1335Q	   missense	   MiSeq	   No	  coverage	  
Caveman	   PD17957a	   4	   106164878	   106164878	   TET2	   CCDS47120.1	   p.T1249N	   missense	   MiSeq	   validated	  
Caveman	   PD17959a	   12	   25398281	   25398281	   KRAS	   CCDS8703.1	   p.G13D	   missense	   MiSeq	   validated	  
	  
PD17959a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17960a	   13	   28608304	   28608305	   FLT3	   CCDS31953.1	   p.D600_L601insSDNEYFYVDFREYEYD	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17960a	   2	   25467449	   25467449	   DNMT3A	   CCDS33157.1	   p.G543C	   missense	   MiSeq	   validated	  
Caveman	   PD17960a	   X	   44938447	   44938447	   KDM6A	   CCDS14265.1	   p.E999*	   nonsense	   MiSeq	   validated	  
	  
PD17960a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17961a	   13	   28608216	   28608219	   FLT3	   CCDS31953.1	   p.?	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Pindel	   PD17962a	   13	   28608274	   28608275	   FLT3	   CCDS31953.1	   p.K602_W603insCREYEYDLK	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Pindel	   PD17962a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17963a	   4	   106157573	   106157573	   TET2	   CCDS47120.1	   p.S825*	   nonsense	   MiSeq	   No	  coverage	  
Caveman	   PD17964a	   21	   36259280	   36259280	   RUNX1	   CCDS13639.1	   p.L71M	   missense	   MiSeq	   No	  coverage	  
	  
PD17964a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   MiSeq	   No	  coverage	  
Pindel	   PD17965a	   20	   31022545	   31022546	   ASXL1	   CCDS13201.1	   p.R678fs*40	   frameshift	   MiSeq	   No	  coverage	  
Caveman	   PD17965a	   Y	   15417990	   15417990	   UTY	   CCDS14783.1	   p.S1018Y	   missense	   MiSeq	   No	  coverage	  
	  
PD17965a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Caveman	   PD17966a	   7	   148511205	   148511205	   EZH2	   CCDS5891.1	   p.R566L	   missense	   MiSeq	   validated	  
Caveman	   PD17966a	   2	   25469038	   25469038	   DNMT3A	   CCDS33157.1	   p.R474S	   missense	   MiSeq	   validated	  
Caveman	   PD17966a	   13	   28592641	   28592641	   FLT3	   CCDS31953.1	   p.D835V	   missense	   MiSeq	   validated	  
Caveman	   PD17966a	   4	   106157119	   106157119	   TET2	   CCDS47120.1	   p.Q674K	   missense	   MiSeq	   No	  coverage	  
	  
PD17966a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   PCR	  +	  capillary	  sequencing	   validated	  
Pindel	   PD17967a	   13	   28608286	   28608287	   FLT3	   CCDS31953.1	   p.Y597_E598insDYVDFREY	   frameshift	   PCR	  +	  agarose	  gel	   validated	  
Caveman	   PD17967a	   1	   115258744	   115258744	   NRAS	   CCDS877.1	   p.G13D	   missense	   MiSeq	   validated	  
Caveman	   PD17967a	   X	   39932971	   39932971	   BCOR	   CCDS48093.1	   p.S543*	   nonsense	   MiSeq	   validated	  
	  
PD17967a	   5	   170837547	   170837548	   NPM1	   CCDS4376.1	   p.W288fs*12	   frameshift	   MiSeq	   validated	  
Pindel	   PD17968a	   2	   25463235	   25463244	   DNMT3A	   CCDS33157.1	   p.F752delF	   inframe	   MiSeq	   validated	  
Caveman	   PD17968a	   1	   115251178	   115251178	   NRAS	   CCDS877.1	   p.G183V	   missense	   MiSeq	   validated	  
Caveman	   PD17968a	   17	   29554540	   29554540	   NF1	   CCDS42292.1	   p.?	   ess	  splice	   MiSeq	   validated	  
	  
Supplementary	  Figure	  Legends	  
Legend	  to	  Supplementary	  Figure	  1	  
A)	  Long-­‐range	  PCR	  on	  genomic	  DNA	  was	  performed	  on	  samples	  PD17948a	  and	  
PD17957a	   to	   check	   for	   the	   presence	   of	   a	  MLL-­‐PTD.	   Sample	   PD17929a	  was	  
used	  as	  a	  negative	  control	  along	  with	  water.	  The	  white	  arrows	  shows	  a	  band	  
at	  >10	  Kb	  suggestive	  of	  an	  MLL-­‐PTD	  in	  the	  two	  test	  samples.	  
B)	   Array	   CHG	   analysis	   of	   sample	   PD17946a	   confirms	   a	   KRAS	   amplification	   in	  
chromosome	   12p,	   and	   a	   5q	   deletion	   that	   involved	   CSF1R	   but	   not	   NPM1	   in	  
keeping	  with	  the	  copy	  number	  pattern	  shown	  in	  Figure	  3A	  (red	  bar).	  
Legend	  to	  Supplementary	  Figure	  2	  
For	  90	  single	  nucleotide	  polymorphisms	  (SNPs)	  covered	  by	  the	  study	  design,	  the	  
allelic	   fraction	  of	   the	  major	  allele	  (defined	  as	  the	  most	  prevalent	   in	  the	  general	  
population)	  is	  plotted	  in	  the	  Y-­‐axis.	  Samples	  are	  plotted	  in	  the	  X-­‐axis.	  Note	  that	  
84.6%	  of	  SNP	  calls	  fall	  close	  to	  the	  50%	  mark	  for	  heterozygous	  SNPs,	  indicating	  
quantitative	   value	   of	   the	   allelic	   fraction	   of	   single	   nucleotide	   substitutions	   in	  
Haloplex	  data.	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